These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 12201621)

  • 21. From the cell to the clinic: a comparative review of the partial D₂/D₃receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease.
    Millan MJ
    Pharmacol Ther; 2010 Nov; 128(2):229-73. PubMed ID: 20600305
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How to succeed in using dopamine agonists in Parkinson's disease.
    Shulman LM
    Eur J Neurol; 2000 May; 7 Suppl 1():9-13. PubMed ID: 11054153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease.
    Utsumi H; Okuma Y; Kano O; Suzuki Y; Iijima M; Tomimitsu H; Hashida H; Kubo S; Suzuki M; Nanri K; Matsumura M; Murakami H; Hattori N;
    Intern Med; 2013; 52(3):325-32. PubMed ID: 23370739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advances in dopamine receptor agonists for the treatment of Parkinson's disease.
    Stocchi F; Torti M; Fossati C
    Expert Opin Pharmacother; 2016 Oct; 17(14):1889-902. PubMed ID: 27561098
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dopamine agonist monotherapy in Parkinson's disease.
    Clarke CE; Guttman M
    Lancet; 2002 Nov; 360(9347):1767-9. PubMed ID: 12480442
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dopaminergic agonists in Parkinson's disease.
    Alonso Cánovas A; Luquin Piudo R; García Ruiz-Espiga P; Burguera JA; Campos Arillo V; Castro A; Linazasoro G; López Del Val J; Vela L; Martínez Castrillo JC
    Neurologia; 2014 May; 29(4):230-41. PubMed ID: 21724302
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early introduction of dopamine agonists in the long-term treatment of Parkinson's disease.
    Ogawa N
    Neurology; 1998 Aug; 51(2 Suppl 2):S13-20. PubMed ID: 9711975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New pharmacotherapy for Parkinson's disease.
    Gottwald MD; Bainbridge JL; Dowling GA; Aminoff MJ; Alldredge BK
    Ann Pharmacother; 1997 Oct; 31(10):1205-17. PubMed ID: 9337447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease.
    Schrag AE; Brooks DJ; Brunt E; Fuell D; Korczyn A; Poewe W; Quinn NP; Rascol O; Stocchi F
    Clin Neuropharmacol; 1998; 21(3):169-75. PubMed ID: 9617508
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of two different dopamine agonists in the management of Parkinson's disease.
    Stocchi F; Berardelli A; Vacca L; Thomas A; De Pandis MF; Modugno N; Valente M; Ruggieri S
    Neurol Sci; 2002 Sep; 23 Suppl 2():S115-6. PubMed ID: 12548370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of dopamine agonists in very elderly patients with Parkinson's disease.
    Shulman LM; Minagar A; Rabinstein A; Weiner WJ
    Mov Disord; 2000 Jul; 15(4):664-8. PubMed ID: 10928576
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pramipexole extended-release: a review of its use in patients with Parkinson's disease.
    Frampton JE
    Drugs; 2014 Dec; 74(18):2175-90. PubMed ID: 25385556
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease.
    Paus S; Brecht HM; Köster J; Seeger G; Klockgether T; Wüllner U
    Mov Disord; 2003 Jun; 18(6):659-67. PubMed ID: 12784269
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The effectiveness and tolerance of piribedil as adjunct therapy to levodopa in patients with Parkinson's disease: a nine month follow up].
    Salazar Tortolero G; Wix Ramos R; Salazar Aladrén P; Jiménez León JC
    Rev Neurol; 2004 Apr 16-30; 38(8):715-9. PubMed ID: 15122540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Dopaminergic agonists in the treatment of Parkinson's disease].
    Supiot F; Sternon J; Zegers de Beyl D
    Rev Med Brux; 2000 Dec; 21(6):493-9. PubMed ID: 11194495
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease.
    Kujawa K; Leurgans S; Raman R; Blasucci L; Goetz CG
    Arch Neurol; 2000 Oct; 57(10):1461-3. PubMed ID: 11030798
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term studies of dopamine agonists.
    Hubble JP
    Neurology; 2002 Feb; 58(4 Suppl 1):S42-50. PubMed ID: 11909984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Piribedil-induced sleep attacks in Parkinson's disease.
    Tan EK
    Fundam Clin Pharmacol; 2003 Feb; 17(1):117-9. PubMed ID: 12588638
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease.
    Clarke CE; Deane KH
    Cochrane Database Syst Rev; 2000; 2001(3):CD001517. PubMed ID: 10908504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.